Literature DB >> 10545675

C-Reactive protein in dilated cardiomyopathy.

K Kaneko1, T Kanda, Y Yamauchi, A Hasegawa, T Iwasaki, M Arai, T Suzuki, I Kobayashi, R Nagai.   

Abstract

The prognosis for patients with idiopathic dilated cardiomyopathy (DCM) is poor, although clinical features are variable. Prediction of outcome has been difficult in individual patients based on laboratory data. In some patients with DCM, myocardial damage secondary to viral or immune-mediated myocardial inflammation may persist. To objectively assess inflammation, we measured plasma concentrations of C-reactive protein (CRP) in 188 patients with idiopathic DCM over 5-8 years. All had dyspnea and fatigue at rest; all patients had a left ventricular ejection fraction less than 40% by echocardiography or by contrast or radionuclide ventriculography. We divided these patients into two groups: patients dying within 5 years following admission (n = 49) and the remainder surviving for at least 5 years (n = 139). CRP concentrations in the patients dying early were significantly higher than in the long-term survivors (1. 05 +/- 1.37 vs. 0.49 +/- 1.04 mg/dl, p < 0.05). Sixty-two percent of the patients with CRP>1.0 died within 5 years. In addition to other laboratory tests including electrocardiography and echocardiography, routine CRP measurements proved to be valuable for identifying high-risk patients who require special treatment strategies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10545675     DOI: 10.1159/000006913

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  18 in total

1.  Inflammatory mediators in chronic heart failure: an overview.

Authors:  Stefan D Anker; Stephan von Haehling
Journal:  Heart       Date:  2004-04       Impact factor: 5.994

Review 2.  Reappraisal of Inflammatory Biomarkers in Heart Failure.

Authors:  Thanat Chaikijurajai; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2020-02

3.  Higher C-reactive protein predicts worse prognosis in acute heart failure only in noninfected patients.

Authors:  Patrícia Lourenço; José Paulo Araújo; Cristiana Paulo; Joana Mascarenhas; Fernando Friões; Ana Azevedo; Paulo Bettencourt
Journal:  Clin Cardiol       Date:  2010-11       Impact factor: 2.882

4.  White blood cell count, C-reactive protein, and incident heart failure in the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Wobo Bekwelem; Pamela L Lutsey; Laura R Loehr; Sunil K Agarwal; Brad C Astor; Cameron Guild; Christie M Ballantyne; Aaron R Folsom
Journal:  Ann Epidemiol       Date:  2011-07-23       Impact factor: 3.797

5.  Inflammatory Markers-Serum Level of C-Reactive Protein, Tumor Necrotic Factor-α, and Interleukin-6 as Predictors of Outcome for Peripartum Cardiomyopathy.

Authors:  A Sarojini; A Sai Ravi Shanker; M Anitha
Journal:  J Obstet Gynaecol India       Date:  2013-08-14

6.  The role of serum VCAM-1 and TNF-α as predictors of mortality and morbidity in patients with chronic heart failure.

Authors:  Ana Savic-Radojevic; Slavica Radovanovic; Tatjana Pekmezovic; Marija Pljesa-Ercegovac; Dragan Simic; Tatjana Djukic; Marija Matic; Tatjana Simic
Journal:  J Clin Lab Anal       Date:  2013-01-24       Impact factor: 2.352

7.  Systemic inflammation in nonischemic dilated cardiomyopathy.

Authors:  Luisa De Gennaro; Natale Daniele Brunetti; Andrea Cuculo; Pier Luigi Pellegrino; Matteo Di Biase
Journal:  Heart Vessels       Date:  2008-11-27       Impact factor: 2.037

8.  Activation of endothelial cells in conduit veins of dogs with heart failure and veins of normal dogs after vascular stretch by acute volume loading.

Authors:  Paolo C Colombo; Sharad Rastogi; Duygu Onat; Valerio Zacà; Ramesh C Gupta; Ulrich P Jorde; Hani N Sabbah
Journal:  J Card Fail       Date:  2009-02-08       Impact factor: 5.712

Review 9.  Biomarkers of inflammation in heart failure.

Authors:  Biykem Bozkurt; Douglas L Mann; Anita Deswal
Journal:  Heart Fail Rev       Date:  2010-07       Impact factor: 4.214

Review 10.  Should a statin be prescribed to every patient with heart failure?

Authors:  Sofia G Tsouli; Evangelos N Liberopoulos; John A Goudevenos; Dimitri P Mikhailidis; Moses S Elisaf
Journal:  Heart Fail Rev       Date:  2007-08-12       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.